By Andrea Figueras Roche said that the European Commission approved Tecentriq SC, a cancer immunotherapy subcutaneous injection for multiple...
January 10, 2024 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: On Sept. 20, 2019, history was made when...
By Stephen Nakrosis LumiraDx said Friday it will sell certain companies related to its point-of-care technology to Roche. Andrew Johnson, Lisa...
By Mauro Orru Roche Holding's Xolair antibody received priority review treatment from the Food and Drug Administration after a late-stage...
By Sabela Ojea Shares of Poseida Therapeutics on Monday climbed after the company said it received positive early results from the phase 1 trial...
By Andrea Figueras Roche said that it has received positive long-term follow-up data and significant overall survival benefit from the Katherine...
By Andrea Figueras Roche said it obtained positive results for its investigational treatment, inavolisib, as a first-line treatment for people...
By Helena Smolak Shares of Germany's Merck KGaA plunged after its experimental drug evobrutinib failed in two late-stage trials of patients...
By Mauro Orru Roche Holding said its investigational treatment, inavolisib, showed promise in a late-stage study to treat patients with breast...
9:42 ET -- Roche is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. The...
By David Sachs and Mauro Orru Roche Holding said it would buy California-based biotechnology company Carmot Therapeutics for up to $3.1 billion...
U.S. index futures are down in Monday’s pre-market trading, reversing some of last week’s gains...
By David Sachs Roche aims to buy Carmot Therapeutics, a California-based pharmaceutical firm developing drugs to treat obesity and diabetes. The...
By Nina Kienle Roche Holding's Genentech and U.S. chip giant Nvidia have entered into a multiyear artificial-intelligence research...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.